Latest Content

Tris Pharma's TRN-257, a low-sodium oxybate, offers a once-nightly treatment option for narcolepsy and idiopathic hypersomnia, enhancing patient care.

Psychiatric Times celebrates 40 years of impactful insights, exploring key topics in psychiatry, including medication management and emerging treatments.

Explore the challenges of protecting privacy in AI chatbots and discover expert insights on navigating data security in a profit-driven landscape.

Teva Pharmaceuticals has submitted an NDA to the FDA for extended-release injectable olanzapine for the treatment of schizophrenia.

Dr. Carrie Soloway's legacy inspires courage in transgender individuals, highlighting the ongoing challenges and triumphs in mental health and identity.

Recent trials reveal oral semaglutide fails to improve cognition or function in early Alzheimer disease, raising questions about its efficacy.

Newron Pharmaceuticals launches a pivotal study on evenamide, targeting treatment-resistant schizophrenia to improve patient outcomes and address unmet needs.

Psychiatric Times celebrates 40 years of advancing mental health care, offering insights, news, and community for psychiatric professionals. Join us in 2026!

Explore innovative solutions to combat burnout in health care, including coaching, psychedelics, and addressing administrative harm for lasting change.

American psychiatry struggles with understanding psychopathology, emphasizing the need to return to its roots for accurate diagnosis and effective treatment.

What were the top psychiatric hits of 2025?

Psychiatry needs compassionate, culturally competent leaders to address mental health challenges and promote innovative solutions for a healthier future.

Incannex Healthcare's PSX-001 shows promise in treating generalized anxiety disorder, offering innovative, effective solutions beyond traditional therapies.